Defense Date


Graduation Date

Summer 8-13-2022


One-year Embargo

Submission Type


Degree Name





School of Pharmacy

Committee Chair

Jelena M. Janjic

Committee Member

Ira Buckner

Committee Member

Wilson Meng

Committee Member

Carl A. Anderson


Nanomedicine, Nanoemulgel, Hydrogels, Nanoemulsion, Drug Delivery, Quality by Design, Anti-inflammatory


Burns are some of the most traumatizing and damaging skin injuries, with the potential of causing extensive internal damage that increases the risk of chronic wound development. Oral and topical analgesics in combination with antibiotics can provide temporary relief and improve wound healing progress for both mild and severe burns. However, recurrent systemic exposure to pain relievers and antibiotics has been associated with adverse side effects including nausea, drowsiness, abdominal pain, etc., and increased risk of new infections or even ulcers. Local and targeted drug delivery systems, such as nanomedicine, have gained attention as potentially more effective alternatives to improve not only patient tolerability/acceptance, but also drug solubility, stability, and efficacy. Our lab has demonstrated that incorporating Resveratrol (RSV), an anti-inflammatory, antioxidant, and antimicrobial organic compound, into oil-in-water nanoemulsions can help improve drug solubility and stability and reduce macrophage production of inflammatory cytokines and small molecules in vitro. It is hypothesized that the formulation of RSV-nanoemulsions dispersed into a hydrogel matrix, assembling nanoemulgels (NEGs), can be optimized as a topical dosage form to support local burn wound healing, using a Quality by Design (QbD) approach. Experiments to test this hypothesis were conducted to meet the following Specific Aims:

(1) Employ QbD strategy to formulate resveratrol-loaded nanoemulgels (RSV-NEGs) and a Screening Design of Experiments (DoE) to determine which parameters may most significantly affect RSV-NEG responses of interest.

(2) Complete a Response Surface DoE to refine the Screening Model (from Specific Aim 1) and further optimize RSV-NEG formulation using Response Surface Models.